Antiplatelet Therapy for Coronary Artery Dissection

(SCAD-ALIGN Trial)

This trial seeks the best treatment for spontaneous coronary artery dissection (SCAD), a rare heart condition primarily affecting women aged 30 to 55. SCAD can cause chest pain and shortness of breath without typical heart disease risk factors. The study compares two strategies: one group will take a single antiplatelet drug, such as aspirin (acetylsalicylic acid or ASA), for three months, while the other will take two drugs (acetylsalicylic acid and clopidogrel) for three months, followed by one drug for nine more months. The goal is to determine if less medication is more effective for this condition. Individuals who have experienced an acute heart problem suspected to be SCAD and are set for conservative treatment might be suitable candidates for this trial. As a Phase 4 trial, this research involves an FDA-approved treatment, aiming to understand its benefits for more patients.

Previous studies have used aspirin safely in many patients with spontaneous coronary artery dissection (SCAD). Research has shown that managing the condition with aspirin is safe for stable patients. Some patients on dual antiplatelet therapy (DAPT), which includes aspirin and another medication, have reported side effects like bruising and heavy menstrual bleeding.

The other medication under study is clopidogrel, which has shown mixed results. Some studies suggest that patients on DAPT, including clopidogrel, may experience higher rates of chest pain and other heart-related issues compared to those taking just one medication. However, clopidogrel alone might reduce the risk of major heart and brain events compared to aspirin alone.

Most treatments for coronary artery dissection involve antiplatelet therapy to prevent further clotting, typically using drugs like acetylsalicylic acid (ASA) alone or in combination with clopidogrel. However, what's exciting about the current protocol under investigation is the strategic duration and combination of these medications. The "moderate APT" approach involves taking ASA for three months and then stopping it, which could potentially reduce medication burden and side effects. Meanwhile, the "intensive APT" method starts with a dual therapy of ASA and clopidogrel for three months, then switches to clopidogrel alone for nine months. This could offer more tailored protection against clotting over a longer period. Researchers are keen to see if these varying regimens could lead to better outcomes, minimize side effects, and improve overall patient management.

This trial will compare two antiplatelet therapy approaches for spontaneous coronary artery dissection (SCAD). Research has shown that using one antiplatelet medication (SAPT) might be safer and more effective than using two (DAPT). Specifically, one study found that using two medications in SCAD could lead to worse outcomes, suggesting that using just one might be better. In this trial, the moderate APT arm involves taking acetylsalicylic acid (ASA) alone, which has reduced the chance of another stroke by 15% in similar situations. The intensive APT arm includes clopidogrel, another medication, which lowered the risk of major heart and brain events by about 14% and has a lower risk of causing bleeding compared to other similar drugs. These treatments prevent excessive blood clotting, which can worsen the condition.¹²⁶⁷⁸